Why did CSL's first-half profit decline?

CSL's first-half profit declined due to weaker albumin and immunoglobulin sales, impacting its core plasma division.

What is CSL doing to address the profit decline?

CSL is accelerating transformation measures and cost-cutting initiatives, and expanding its share buyback program by $250 million.

What is CSL's outlook for fiscal 2026?

CSL reaffirmed its fiscal 2026 outlook, expecting modest revenue growth and a return to mid-single-digit underlying profit growth.

Home / Business and Economy / CSL Profit Dips Amid Weaker Sales, Policy Pressures

CSL Profit Dips Amid Weaker Sales, Policy Pressures

11 Feb

•

Summary

First-half profit declined due to lower albumin and immunoglobulin sales.
CSL is expanding its share buyback by $250 million to show financial strength.
The company is accelerating transformation and cost-cutting measures.

CSL Profit Dips Amid Weaker Sales, Policy Pressures

Australian biotechnology giant CSL experienced a decline in its first-half profit, reporting $1.92 billion on a constant currency basis for the six months ending December 31, compared to $2.11 billion in the prior year. Total revenue decreased by 4% to $8.33 billion. The core plasma division, CSL Behring, saw a 7% revenue drop, with albumin sales falling significantly by 27% and immunoglobulin sales down 6%.

In response to the softer performance, CSL is intensifying its transformation measures, including cost-cutting initiatives. The company has already achieved about 60% of its fiscal 2026 targeted cost savings. To signal financial stability and reassure investors, CSL announced plans to expand its share buyback program by an additional $250 million.